BioCryst Pharmaceuticals, Inc. approved a plan to discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama, as part of a strategic evolution to focus on rare disease pipeline. The implementation of the Plan is expected to be substantially complete by the end of 2026. The company is currently unable to estimate the total costs associated with the following: contract termination, lease termination, employee termination benefits, and severance. BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes drugs for rare diseases.

On June 11, 2026, BioCryst Pharmaceuticals stockholders approved a proposal to amend and restate the Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000 shares. The company also elected directors Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse, ratified Ernst & Young LLP as independent auditors, and passed a non-binding advisory vote on executive compensation. BioCryst Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare diseases.